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systematic RTT QA procedures. These measures are 
compulsory for patient safety and quality but also need to be 
balanced with available resources. RTTs, sensitized to this 
issue and due to their position in the RT process, are 
therefore good candidates to become quality managers (QM) 
in a RT department.  
Since 2010, the Belgian national cancer plan has allowed for 
the progressive introduction of quality management systems 
(QMS) within the licensed radiotherapy departments.  
Between 2010 and 2013, the departments have been funded 
in order to hire one FTE QM whose role is to implement a 
QMS in the department in order to improve the processes and 
patient safety within the RT departments. This includes the 
recording and analysis of near-incidents and incidents 
through the PRISMA-RT (Prevention and Recovery Information 
System for Monitoring and Analysis in RadioTherapy) program. 
A short survey carried out in 2014 demonstrated that 41% of 
the hired QMs had a RTT professional background. Although 
lacking some theoretical background, RTTs are well adapted 
for the QM role and, and along with the non-RTT QMs,  are 
successful in implementing QMS within their departments as 
demonstrated by the preliminary results of the national 
clinical auditing program carried out by the Federal College 
of Radiotherapy using the IAEA methodology (QUATRO[1] 
(Quality Assurance Team for Radiation Oncology)).  
Furthermore, all RT QMs have decided to come together to 
form an association known as QMRT.be (Belgian association of 
Quality Managers in RadioTherapy) whose aim is to integrate 
the procedural requirements of a QMS within the clinical 
reality of patient treatment by acting as support system for 
all RT QMs. Since then, this group has been implicated in 
various projects such as PRISMA-RT expert group and QUATRO 
audits.  
 [1] Comprehensive Audits of Radiotherapy Practice: a tool 
for Quality Improvement. IAEA, Vienna, 2007 
(http://www.iaea.org/books). 
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Healthcare is inclining in the western world with growing 
costs. In the Netherlands it is assumed for instance that cost 
may rise from 13% GDP (90 billion euro) towards 30% GDP in 
2030. At the same time the public, patients, governement 
and  insurance companies question the quality of healthcare. 
From that perspective providers are asked to deliver a broad 
and often changing set of quality indicators to the different 
stakeholders to be used in public for ranking, transparancy 
and choosing information. In the “slipstream” of asking 
different indicators, often different levels for quality are 
defined by the stakeholders.  Irrespective of the perspective 
of “the outside” this will not give a proper insight in quality 
of healthcare and is not the way to initiate improvements of 
healthcare. The latter being important while improvement 
always goes with cost reduction. Quality improvement being 
to only proper way to initiate cost efficacy in healthcare.  
From that perspective already 8 years ago the professional 
boards of medical specialists started “clinical registries”. 
Bottom up collecting clinical information with an online  
feedback and nationwide benchmark, so professionals could 
see whether they are underperfoming or not. During the 
years this proved to be a strong improvement tool in all fields 
were clinical registries were implemented.  Development, 
implementation and exploitation of these registries is 
serviced by the Dutch Institute for Clinical Auditing (DICA; 
www.clinicalaudit.nl) a non-profit organisation driven by 
medical professinals.  At this time more than 17 registries are 
serviced by DICA, using strict preconditions regarding privacy, 
ownership , transparancy, autonomy of professional 
organisations etc. At his time existing registries are 
multidisciplinary extended, results are combined with Patient 
Related Outcome Maesurment’s (PROM’s) and financial data. 
In this way improvement of care at affordable costs with 
satisfied patients comes in reach. The next step is to allign 
data sets to come to global comparisons. During the  session 
“Advanced technology assessment; Quality management in an 
era of rapidly evolving radiology technology” more details 
regarding background, preconditions, results and future 
perspectives will be presented.  
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A better understanding of tumour biology has led to the 
development of targeted therapies, in which a drug is 
designed to disrupt a specific biochemical pathway important 
for tumour cell survival or proliferation.  The introduction of 
these drugs into the clinic has shown that patients can vary 
widely in their responses.  Molecular imaging is likely to play 
an increasingly important role in predicting and detecting 
these responses and thus in guiding treatment in individual 
patients [1].  We have been developing methods for 
detecting the early responses of tumours to therapy, 
including metabolic imaging with hyperpolarized 13C-labelled 
substrates, which we have used both to detect treatment 
response and to investigate the tumour microenvironment 
(reviewed in [2-4]).  Exchange of hyperpolarized 13C label 
between lactate and pyruvate [5] and net flux of label 
between glucose and lactate [6] have been shown to 
decrease post-treatment and hyperpolarized [1,4-
13C]fumarate has been shown to detect subsequent cell 
necrosis [7,8].  Tumour pH can be imaged using 
hyperpolarized H13CO3¯ [9] and redox state can be 
determined by monitoring the oxidation and reduction of [1-
13C]ascorbate and [1-13C]dehydroascorbate respectively [10]. 
 More recently we have shown that we can follow, using 
hyperpolarized [1-13C]pyruvate, the progression of pancreatic 
precursor lesions, in a genetically engineered mouse model of 
the disease, which potentially could be used clinically to 
guide earlier intervention. 
  
1.  Brindle, K. Nature Rev Cancer 8, 94-107 (2008). 
2.  Gallagher, F., et al. Prog. NMR Spectrosc. 55, 285-295 
(2009). 
3.   Brindle, K.M., et al. Magn Reson Med 66, 505-519 (2011). 
4.   Brindle, K. Brit. J. Radiol. 85, 697-708 (2012). 
5.   Day, S.E., et al. Nature Med 13, 1382-1387 (2007). 
6.   Rodrigues, T.B., et al. Nat Med 20, 93-97 (2014). 
7.   Gallagher, F.A., et al. Proc Natl Acad Sci U S A 106, 
19801-19806 (2009). 
8.   Bohndiek, S.E., et al. Cancer Research 72, 854-864 
(2012). 
9.   Gallagher, F., et al. Nature 453, 940-943 (2008). 
